A new guide for a changing PBC treatment landscape
The American Gastroenterological Association and the American Association for the Study of Liver Diseases have released a joint, drug-focused guideline on primary biliary cholangitis, or PBC. According to the Medical Xpress report, it is the first guideline from the two groups to evaluate newer medications for the disease.
PBC is a long-term autoimmune liver disease and the most common cholestatic disease in adults. Cholestatic diseases involve impaired bile flow, and PBC care often requires decisions about diagnosis, treatment response and symptom management over time. The new document is intended to give clinicians evidence-based recommendations as the available treatment options change.
The guideline was published in Gastroenterology and Hepatology, the report says. It is designed for a broad clinical audience, an important point because most people living with PBC are cared for by general gastroenterologists rather than hepatology specialists. The societies’ stated aim is to make current evidence and standards of care more accessible across that wider group of clinicians.
Focus on diagnosis, escalation and symptoms
The guideline addresses several practical challenges in PBC care. These include diagnosing patients with less common antibody profiles, deciding when treatment should move beyond first-line therapy, and managing PBC-related itching. It provides six recommendations covering diagnosis and management, according to the source report.
Those topics reflect the way clinical decisions can diverge between patients. A person’s disease characteristics, risk of progression, symptoms and preferences may not point to the same treatment path as another patient’s. The joint guidance therefore supports a personalized approach rather than a single uniform sequence for every person with PBC.
David N. Assis, a guideline author quoted in the report, said the treatment landscape has changed substantially over the past five years. The source notes two major developments behind the timing of the document: newer options for second-line therapy and the removal of a treatment that had been used for the past decade.
A shift after obeticholic acid’s withdrawal
The report specifically notes that obeticholic acid was withdrawn from the US market late in 2025. That change matters for clinicians and patients who must reassess treatment choices when a previously available therapy is no longer part of the US treatment landscape.
The new guideline complements broader AASLD PBC guidance issued in 2018 and 2021. Those earlier documents addressed PBC care more comprehensively, while the new guideline puts particular emphasis on drug treatment and second-line options. Together, the sources are meant to help clinicians navigate a care environment in which the evidence, available medicines and treatment choices are evolving.
The report frames the clinical objective as intervening early and tailoring care over time to slow disease progression while preserving quality of life. That objective brings diagnosis, drug selection and symptom treatment into the same practical conversation. It also explains why the guideline includes issues such as itching: symptoms can materially affect a patient’s daily life even as clinicians track disease-related risk.
What clinicians and patients can take from it
- The guideline is the first joint AGA-AASLD document focused on evaluating newer PBC medications.
- It offers six evidence-based recommendations on diagnosis and management.
- It addresses less common antibody profiles, choices after first-line therapy and PBC-related itching.
- It is intended to support general gastroenterologists as well as liver specialists.
- Its release follows recent changes in second-line treatment options and the US withdrawal of obeticholic acid.
The guidance does not remove the need for individualized clinical judgment. Instead, it supplies a current evidence-based framework for decisions that have become more complex as treatment options have shifted. For patients, the core message is that PBC management may need to be revisited over time, with attention to progression risk, disease features, symptoms and personal preferences.
For the broader health system, the guideline’s significance lies in its focus on practical care. As PBC treatment continues to evolve, a drug-focused reference jointly developed by two major US gastroenterology and liver-disease organizations may help bring more consistent, current decision-making to the clinicians who care for most patients with the condition.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
